Aerpio Pharmaceuticals, Inc. (ARPO)의 가격은 얼마입니까?

Aerpio Pharmaceuticals, Inc. (ARPO)의 가격은 $2.20입니다.

Aerpio Pharmaceuticals, Inc. (ARPO)의 시가 총액은 무엇입니까?

Aerpio Pharmaceuticals, Inc. (ARPO)의 시가 총액은 $40.53M입니다.

Aerpio Pharmaceuticals, Inc. (ARPO) 수익

Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.

연도	매출	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

매출

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	매출	매출 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

매출

매출 차이

국가